{
  "report_rows": [
    {
      "kpi": "Adj. Diluted EPS (Q3 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~$4.45 vs. cons $4.35",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. Healthcare Solutions OI (Q3 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~$960M vs. cons $940M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (Q3 FY26)",
      "prediction": "IN-LINE",
      "answer": "pred ~$84.5B vs. cons $84.4B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adj. EPS (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$17.65-$17.90 maintained vs. cons $17.79",
      "confidence": "HIGH"
    },
    {
      "kpi": "Revenue Growth (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 4-6% maintained vs. cons at midpoint",
      "confidence": "HIGH"
    },
    {
      "kpi": "Q4 Cadence / Biosimilar Commentary",
      "prediction": "BETTER",
      "answer": "stabilization language; Q4 strongest quarter reiterated",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.5,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE \u2014 EPS beat absorbed into modest upward estimate revisions; no large revision catalyst from maintained FY guide; stock consolidates near post-print level",
  "day5_confidence": "MEDIUM"
}